Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients

Diabetes Mellitus, Type 2 Clinical Trial

— GDC  

Official title:

Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01055093
• Other study ID #: GDC-Study-01
• Status: Recruiting
• Start date: September 2005
• Est. completion date: September 2035

Study information

• Verified date: June 2023
• Source: German Diabetes Center
• Contact: Robert Wagner, Prof., MD
• Phone: +49-211-3382
• Email: robert.wagner[@]ddz.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the prospective observational GDC-Study in patients with newly diagnosed diabetes mellitus aged 18-69 years at inclusion into the study is to characterize in detail the clinical, metabolical and immunological phenotype and monitor the progression of the disease and to compare the phenotype to glucose tolerant humans of similar age, body mass and sex distribution.

Description:

In detail, the following questions will be answered:

1. Are there different phenotypes with respect to insulin secretion, insulin sensitivity, micro- and macrovascular status and diabetic neuropathy at time of diagnosis?

2. Which factors modify the progression of the disease (Nutrition, subclinical inflammation, energy metabolism and physical activity)?

3. Can we identify subgroups at baseline with different progression of the disease? Patients are thoroughly examined at baseline and after 2, 5, and 10 years with annual telephone contacts in between.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: September 2035
• Est. primary completion date: September 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of diabetes mellitus according to ADA criteria

• Age 18-69

• Diabetes duration since diagnosis < 12 months

• Control cohort: proven normal glucose tolerance according to ADA criteria

Exclusion Criteria:

• Diabetes mellitus category 3 B-H (ADA criteria)

• Pregnancy

• Severe renal, liver or heart disease

• malignant cancer

• severe psychiatric illness or addiction

• participation in an intervention trial

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2

Locations

Country	Name	City	State
Germany	German Diabetes Center	Düsseldorf	North-Rhine Westphalia

Sponsors (1)

Lead Sponsor	Collaborator
German Diabetes Center

Country where clinical trial is conducted

Germany, 

References & Publications (24)

Apostolopoulou M, Strassburger K, Herder C, Knebel B, Kotzka J, Szendroedi J, Roden M; GDS group. Metabolic flexibility and oxidative capacity independently associate with insulin sensitivity in individuals with newly diagnosed type 2 diabetes. Diabetolog — View Citation

Bodis K, Jelenik T, Lundbom J, Markgraf DF, Strom A, Zaharia OP, Karusheva Y, Burkart V, Mussig K, Kupriyanova Y, Ouni M, Wolkersdorfer M, Hwang JH, Ziegler D, Schurmann A, Roden M, Szendroedi J; GDS Study Group. Expansion and Impaired Mitochondrial Effic — View Citation

Gancheva S, Bierwagen A, Kaul K, Herder C, Nowotny P, Kahl S, Giani G, Klueppelholz B, Knebel B, Begovatz P, Strassburger K, Al-Hasani H, Lundbom J, Szendroedi J, Roden M; German Diabetes Study (GDS) Group. Variants in Genes Controlling Oxidative Metaboli — View Citation

Grobosch S, Kuske S, Linnenkamp U, Ernstmann N, Stephan A, Genz J, Begun A, Haastert B, Szendroedi J, Mussig K, Burkart V, Roden M, Icks A; GDS Group. What information needs do people with recently diagnosed diabetes mellitus have and what are the associa — View Citation

Kanti G, Anadol-Schmitz E, Bobrov P, Strassburger K, Kahl S, Zaharia OP, Sarabhai T, Karusheva Y, Burkart V, Markgraf DF, Trenkamp S, Ziegler D, Szendroedi J, Roden M; GDS Group. Vitamin B12 and Folate Concentrations in Recent-onset Type 2 Diabetes and th — View Citation

Knebel B, Strassburger K, Szendroedi J, Kotzka J, Scheer M, Nowotny B, Mussig K, Lehr S, Pacini G, Finner H, Kluppelholz B, Giani G, Al-Hasani H, Roden M; German Diabetes Study Group. Specific Metabolic Profiles and Their Relationship to Insulin Resistanc — View Citation

Kossler T, Bobrov P, Strassburger K, Kuss O, Zaharia OP, Karusheva Y, Moser C, Bodis K, Burkart V, Roden M, Szendroedi J; GDS Group. Impact of mixed meal tolerance test composition on measures of beta-cell function in type 2 diabetes. Nutr Metab (Lond). 2 — View Citation

Kupriyanova Y, Zaharia OP, Bobrov P, Karusheva Y, Burkart V, Szendroedi J, Hwang JH, Roden M; GDS group. Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. J Hepatol. 2021 May;74(5):1028-1037. doi: — View Citation

Maalmi H, Herder C, Strassburger K, Urner S, Jandeleit-Dahm K, Zaharia OP, Karusheva Y, Bongaerts BWC, Rathmann W, Burkart V, Szendroedi J, Roden M. Biomarkers of Inflammation and Glomerular Filtration Rate in Individuals with Recent-Onset Type 1 and Type — View Citation

Menart-Houtermans B, Rutter R, Nowotny B, Rosenbauer J, Koliaki C, Kahl S, Simon MC, Szendroedi J, Schloot NC, Roden M; German Diabetes Study Group. Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: — View Citation

Puttgen S, Bonhof GJ, Strom A, Mussig K, Szendroedi J, Roden M, Ziegler D. Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy. J Clin Endocrinol Metab. 2019 Dec 1;104(12):6220-6228. doi: 10.1210/jc.2019-01072. — View Citation

Rathmann W, Strassburger K, Bongaerts B, Kuss O, Mussig K, Burkart V, Szendroedi J, Kotzka J, Knebel B, Al-Hasani H, Roden M; GDS Group. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diag — View Citation

Rohling M, Strom A, Bonhof G, Puttgen S, Bodis K, Mussig K, Szendrodi J, Markgraf D, Lehr S, Roden M, Ziegler D; German Diabetes Study Group. Differential Patterns of Impaired Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnos — View Citation

Schroder K, Szendroedi J, Benthin A, Gontscharuk V, Ackermann P, Volker M, Steingrube N, Nowotny B, Ziegler D, Mussig K, Geerling G, Kuss O, Roden M, Guthoff R; GDS Cohort. German Diabetes Study - Baseline data of retinal layer thickness measured by SD-OC — View Citation

Simon MC, Moller-Horigome A, Strassburger K, Nowotny B, Knebel B, Mussig K, Herder C, Szendroedi J, Roden MW; German Diabetes Study Group. Correlates of Insulin-Stimulated Glucose Disposal in Recent-Onset Type 1 and Type 2 Diabetes. J Clin Endocrinol Meta — View Citation

Szendroedi J, Saxena A, Weber KS, Strassburger K, Herder C, Burkart V, Nowotny B, Icks A, Kuss O, Ziegler D, Al-Hasani H, Mussig K, Roden M; GDS Group. Cohort profile: the German Diabetes Study (GDS). Cardiovasc Diabetol. 2016 Apr 7;15:59. doi: 10.1186/s1 — View Citation

van Gemert T, Wolwer W, Weber KS, Hoyer A, Strassburger K, Bohnau NT, Bruggen MA, Ovelgonne K, Gossmann EM, Burkart V, Szendroedi J, Roden M, Mussig K; GDS Group. Cognitive Function Is Impaired in Patients with Recently Diagnosed Type 2 Diabetes, but Not — View Citation

Weber KS, Knebel B, Strassburger K, Kotzka J, Stehle P, Szendroedi J, Mussig K, Buyken AE, Roden M; GDS Group. Associations between explorative dietary patterns and serum lipid levels and their interactions with ApoA5 and ApoE haplotype in patients with r — View Citation

Weber KS, Nowotny B, Strassburger K, Pacini G, Mussig K, Szendroedi J, Herder C, Roden M; GDS Group. The Role of Markers of Low-Grade Inflammation for the Early Time Course of Glycemic Control, Glucose Disappearance Rate, and beta-Cell Function in Recentl — View Citation

Weber KS, Strassburger K, Pacini G, Nowotny B, Mussig K, Szendroedi J, Herder C, Roden M; German Diabetes Study group. Circulating adiponectin concentration is inversely associated with glucose tolerance and insulin secretion in people with newly diagnose — View Citation

Zaharia OP, Bobrov P, Strassburger K, Bodis K, Karusheva Y, Scholz M, Markgraf DF, Burkart V, Schloot NC, Mussig K, Szendroedi J, Roden M; GDS Group. Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus. J Clin Endocrin — View Citation

Zaharia OP, Strassburger K, Knebel B, Kupriyanova Y, Karusheva Y, Wolkersdorfer M, Bodis K, Markgraf DF, Burkart V, Hwang JH, Kotzka J, Al-Hasani H, Szendroedi J, Roden M; GDS Group. Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic — View Citation

Zaharia OP, Strassburger K, Strom A, Bonhof GJ, Karusheva Y, Antoniou S, Bodis K, Markgraf DF, Burkart V, Mussig K, Hwang JH, Asplund O, Groop L, Ahlqvist E, Seissler J, Nawroth P, Kopf S, Schmid SM, Stumvoll M, Pfeiffer AFH, Kabisch S, Tselmin S, Haring — View Citation

Ziegler D, Strom A, Kupriyanova Y, Bierwagen A, Bonhof GJ, Bodis K, Mussig K, Szendroedi J, Bobrov P, Markgraf DF, Hwang JH, Roden M; GDS Group. Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 — View Citation

* Note: There are 24 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of insulin sensitivity (M-Value)	measurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp	2 and 5 years
Secondary	Change of insulin secretion	measurement of insulin secretion with glucagon test, mixed-meal test and intravenous glucose tolerance test	2 and 5 years
Secondary	Incidence of any diabetic complication	The prevalence of diabetic complications	2-10 years

External Links

•   Official website of the German Diabetes Center